Conference
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions
Authors
Pollack C; Reilly PA; Verhamme P; Bernstein R; Dubiel R; Eikelboom J; Huisman M; Hylek E; Kam C-W; Kamphuisen PW
Volume
13
Pagination
pp. 85-85
Publisher
WILEY-BLACKWELL
Publication Date
June 1, 2015
Conference proceedings
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
ISSN
1538-7933